Product Description: Leucomycin (kitasamycin) is a macrolide antibiotic produced by Streptomyces kitasatoensis with broad-spectrum antibacterial activity[1][2][3][4][5].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Iwata K, et al. Studies on the in vitro Antibacterial Activity of Leucomycin[J]. The Journal of Antibiotics, Series A, 1962, 15(6): 258-265./[2]PACHTMAN EA, et al. Leucomycin; a new antibiotic. Am J Pharm Sci Support Public Health. 1958 Oct;130(10):342-4./[3]Vézina C, et al. Biosynthesis of kitasamycin (leucomycin) by leucine analog-resistant mutants of Streptomyces kitasatoensis. Antimicrob Agents Chemother. 1979 May;15(5):738-46./[4]La T, et al. Testing the efficacy of kitasamycin for use in the control and treatment of swine dysentery in experimentally infected pigs. Aust Vet J. 2019 Sep 17./[5]Hassan AB, et al. Pharmacokinetics and tissue residues of kitasamycin in healthy and diseased broilers. Dtsch Tierarztl Wochenschr. 1990 Aug;97(8):315-7.
CAS Number: 1392-21-8
Molecular Weight: N/A
Research Area: Infection
Solubility: DMSO : 110 mg/mL (ultrasonic)/H2O : < 0.1 mg/mL
Target: Antibiotic;Bacterial
English
Deutsch
